Alexandre Santos

Dr. Alexandre Santos


Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 July 2016 in Acta Oncologica
Verified
Journal Article
Closed access
ASAlexandre Santos
Alexandre Santos
Loredana G MarcuLoredana G Marcu
Loredana G Marcu
CWChia M. Wong
Chia M. Wong
EBEva Bezak
Eva Bezak
Aims: There is evidence towards the induction of second primary cancers (SPCs) after breast radiotherapy (RT). Organs, such as the lungs and the esophagus, have been identified as common sites for SPC formation. As a result, the current study investigated the risk of secondary carcinogenesis associated with particular RT techniques for breast cancer; including whole breast, segmented breast, partial breast and mammosite brachytherapy. Methods: In this study, seven breast cancer patients had all major organs contoured on their planning computed tomography (CT) images. Whole breast, segmented breast, accelerated partial breast irradiation (APBI) and mammosite boost treatment plans were generated for each patient using Pinnacle3 treatment planning system. Differential dose-volume histograms were generated for a number of critical structures: bladder, brain and central nervous system (CNS), breast, colon, liver, lung, mouth and pharynx, esophagus, ovary, salivary gland, small intestine, stomach, and uterus. The lifetime attributed risk (LAR) of cancer induction was estimated using the Schneider et al. excess absolute risk models and dose-volume histograms for the above organs. Results: The sites with the highest LAR estimates were the ipsilateral and contralateral lungs, and contralateral breast for all treatment techniques. For all sites, the LAR estimates for the segmented breast and mammosite treatments were lower than those for the whole breast and APBI treatments. For right-sided target volumes the liver also resulted in high LAR estimates, with all techniques having a LAR greater than 20 per 10 000 person-years (PY), except for mammosite with a mean LAR estimate of 13.2 per 10 000 PY. For left-sided target volumes the stomach also resulted in high LAR estimates, with both whole breast and APBI having a LAR greater than 20 per 10 000 PY, and mammosite the lowest with a LAR of 8.3 per 10 000 PY. Conclusion: It is concluded that the lungs and contralateral breast showed high LAR estimates.

1 June 2013 in Radiation Measurements
Verified
Journal Article
Closed access
ASAlexandre Santos
Alexandre Santos
MMMohammad Mohammadi
Mohammad Mohammadi
JAJohan Asp
Johan Asp
TMTanya M. Monro
Tanya M. Monro
SAShahraam Afshar
Shahraam Afshar

16 August 2013 in European Journal of Cancer Care
Verified
Journal Article
Closed access
PDF file
Loredana G MarcuLoredana G Marcu
Loredana G Marcu
ASAlexandre Santos
Alexandre Santos
EBEva Bezak
Eva Bezak
Technological advances in both diagnosis and treatment of breast cancer lead to early detection and better treatment management. Consequently, the population of long‐term survivors is on the rise. The risk of developing second cancers among breast cancer survivors was shown to be higher than that for the general population. The aim of this work was to review the literature on the risk of second primary cancer (SPC) after breast irradiation. Pubmed search of population‐based studies on SPC after breast irradiation was conducted and the findings (in terms of Standardised Incidence Ratio) were collated and discussed. Several studies confirmed the link between breast tumour irradiation and risk of SPC, showing a small, but valid risk. There are, however, confounding factors that can either underestimate or overestimate risks: misclassification of tumour status, genetic inheritance, smoking, environmental factors, and the lack of accurate data in cancer registries. While isolating these potential triggers might be difficult, this approach would allow better discernability between radiotherapy‐related risks and those generated by other factors. It is also important to evaluate the current status of treatment‐related late effects and to lower such risks by minimising the dose delivered to normal tissues.

16 December 2022 in Radiation Physics and Chemistry
Verified
Journal Article
Closed access
LYLe Yu
Le Yu
Pei Lay YapPei Lay Yap
Pei Lay Yap
ASAlexandre Santos
Alexandre Santos
DTDiana Tran
Diana Tran
Dusan LosicDusan Losic
Dusan Losic

2 May 2022 in Cancers
Verified
Journal Article
Open access
PDF file
ASAlexandre Santos
Alexandre Santos
SPScott Penfold
Scott Penfold
PGPeter Gorayski
Peter Gorayski
HLHien Le
Hien Le
Hypofractionated radiotherapy is an attractive approach for minimizing patient burden and treatment cost. Technological advancements in external beam radiotherapy (EBRT) delivery and image guidance have resulted in improved targeting and conformality of the absorbed dose to the disease and a reduction in dose to healthy tissue. These advances in EBRT have led to an increasing adoption and interest in hypofractionation. Furthermore, for many treatment sites, proton beam therapy (PBT) provides an improved absorbed dose distribution compared to X-ray (photon) EBRT. In the past 10 years there has been a notable increase in reported clinical data involving hypofractionation with PBT, reflecting the interest in this treatment approach. This review will discuss the reported clinical data and radiobiology of hypofractionated PBT. Over 50 published manuscripts reporting clinical results involving hypofractionation and PBT were included in this review, ~90% of which were published since 2010. The most common treatment regions reported were prostate, lung and liver, making over 70% of the reported results. Many of the reported clinical data indicate that hypofractionated PBT can be well tolerated, however future clinical trials are still needed to determine the optimal fractionation regime.

1 February 2015 in Radiation Measurements
Verified
Journal Article
Closed access
ASAlexandre Santos
Alexandre Santos
MMMohammad Mohammadi
Mohammad Mohammadi
SAShahraam Afshar
Shahraam Afshar